Epithelial membrane antigen (EMA) or MUC1 expression in monocytes and monoblasts

• Published in: Pathology Vol. 35; no. 5; pp. 422 - 427
• Main Authors: Leong, Chooi-Fun, Raudhawati, Osman, Cheong, Soon-Keng, Sivagengei, Kulaveerasingam, Hamidah, Hussin Noor
• Format: Journal Article
• Language: English
• Published: London Elsevier B.V 01.10.2003; Informa UK Ltd; Taylor and Francis
• Subjects: acute myeloid leukaemia; acute myeloid leukemia; Antigens, CD - analysis; Antigens, CD - metabolism; Biological and medical sciences; Biomarkers - analysis; Bone Marrow Cells - metabolism; Bone Marrow Cells - pathology; Cell Lineage; Cross-Sectional Studies; EMA; Flow Cytometry; Hematologic and hematopoietic diseases; Hematology; Humans; Immunophenotyping; Investigative techniques, diagnostic techniques (general aspects); Leukemia, Monocytic, Acute - metabolism; Leukemia, Monocytic, Acute - pathology; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Medical sciences; monoblasts; monocytes; Monocytes - metabolism; Monocytes - pathology; Mucin-1 - analysis; Mucin-1 - metabolism; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques; Stem Cells - metabolism; Stem Cells - pathology; EMA; monocytes; acute myeloid leukemia; acute myeloid leukaemia; monoblasts; Human; Immunohistochemistry; Monocyte; Leukemia; Malignant hemopathy; Gene expression; Differential diagnostic; Antigen; Anatomic pathology; Monoblast; Mucin; Epithelial cell; Membrane; Diagnosis; Technique
• ISSN: 0031-3025; 1465-3931
• DOI: 10.1080/00313020310001602576

Epithelial membrane antigen (EMA) or MUC1 belongs to a heterogeneous group of heavily glycosylated proteins and is expressed in most normal and epithelial neoplastic cells. EMA is also expressed in plasma cells, anaplastic large cell lymphoma (Ki-1 antigen), malignant histiocytosis and erythroleukaemia. In 1996, Cheong et al. (Hematology 1996; 1: 223) demonstrated the positive expression of EMA in monoblasts. Since there were very few useful markers for differentiating subtypes of acute myeloid leukaemia with a monocytic component from the those without, a study was conducted to evaluate the prevalence of EMA expression and its relationship with known markers for monocytic–macrophage lineage (CD11c, CD14 and intracellular CD68) in monocytes and monoblasts. EMA detection was performed by flow cytometry in monocytes and monoblasts. EMA expression was compared with other known markers of monocytic–macrophage lineage (CD11c, CD14 and intracellular CD68). Samples of purified monocytes were obtained from 20 healthy volunteers. Twenty-two cases of monocytic AML (M4 and M5) were studied and controls were selected from 20 cases of acute lymphoblastic leukaemia (ALL) and 18 cases of non-monocytic AML (M0, M1, M2, M3, and M7). EMA was shown to be expressed strongly on the surface of all purified monocytes. EMA expression was observed on blast cells in 18/22 (81.8%) cases of AML M4 and M5, but not in that of non-monocytic AML or ALL. In this study EMA monoclonal antibody has demonstrated a strong association (P<0.001) with all the other known markers of monocytic–macrophage lineage in acute leukaemia subtypes. EMA had also shown 100% specificity and 81.8% sensitivity in the diagnosis of AML M4 and M5. The monoclonal antibody EMA (clone E29) is a useful marker in the classification of acute myeloid leukaemia and can be used as a supplementary analysis for the diagnosis of acute leukemia with monocytic involvement.